Denali Therapeutics Inc.

Denali Therapeutics Inc.verified

DNLI

Price:

$19.21

Market Cap:

$2.74B

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's d...[Read more]

Industry

Biotechnology

IPO Date

2017-12-08

Stock Exchange

NASDAQ

Ticker

DNLI

The PE Ratio as of May 2024 (TTM) for Denali Therapeutics Inc. (DNLI) is -20.44

According to Denali Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -20.44. This represents a change of 431.49% compared to the average of -3.85 of the last 4 quarters.

Denali Therapeutics Inc. (DNLI) Historical PE Ratio (quarterly & annually)

How has DNLI PE Ratio performed in the past?

The mean historical PE Ratio of Denali Therapeutics Inc. over the last ten years is 1.04. The current -20.44 PE Ratio has changed -197145.27% with respect to the historical average. Over the past ten years (40 quarters), DNLI's PE Ratio was at its highest in in the December 2020 quarter at 10.27. The PE Ratio was at its lowest in in the June 2021 quarter at -39.19.

Quarterly (TTM)
Annual

Average

1.04

Median

-8.43

Minimum

-52.80

Maximum

128.31

Denali Therapeutics Inc. (DNLI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Denali Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.89%

Maximum Annual PE Ratio = 128.31

Minimum Annual Increase = -1622.46%

Minimum Annual PE Ratio = -52.80

Quarterly (TTM)
Annual
YearPE RatioChange
2023-20.3089.56%
2022-10.71-42.59%
2021-18.65-114.54%
2020128.31-1622.46%
2019-8.43-84.04%
2018-52.801.89%
2017-2.6566.87%
2016-1.59-58.60%

Denali Therapeutics Inc. (DNLI) Average PE Ratio

How has DNLI PE Ratio performed in the past?

The current PE Ratio of Denali Therapeutics Inc. (DNLI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-16.55

5-year avg

14.04

10-year avg

1.04

Denali Therapeutics Inc. (DNLI) PE Ratio vs. Peers

How is DNLI’s PE Ratio compared to its peers?

Denali Therapeutics Inc.’s PE Ratio is less than Homology Medicines, Inc. (-0.01), less than Stoke Therapeutics, Inc. (-6.14), less than Atreca, Inc. (-0.04), less than Black Diamond Therapeutics, Inc. (-3.18), less than 4D Molecular Therapeutics, Inc. (-11.85), less than Ascendis Pharma A/S (-13.63), less than Apellis Pharmaceuticals, Inc. (-11.97), greater than BeiGene, Ltd. (-26.39), less than Akero Therapeutics, Inc. (-6.06), greater than Blueprint Medicines Corporation (-21.96), less than Legend Biotech Corporation (-16.18), less than Vaxcyte, Inc. (-17.58), less than Travere Therapeutics, Inc. (-2.95), less than Cerevel Therapeutics Holdings, Inc. (-16.30), less than Avidity Biosciences, Inc. (-10.47), less than Revolution Medicines, Inc. (-12.91), less than Day One Biopharmaceuticals, Inc. (-5.71), less than SpringWorks Therapeutics, Inc. (-9.22), less than Monte Rosa Therapeutics, Inc. (-1.85), less than Design Therapeutics, Inc. (-4.20), less than Werewolf Therapeutics, Inc. (-4.88), less than Ikena Oncology, Inc. (-0.92),

Build a custom stock screener for Denali Therapeutics Inc. (DNLI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Denali Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Denali Therapeutics Inc. (DNLI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Denali Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Denali Therapeutics Inc.'s PE Ratio?

How is the PE Ratio calculated for Denali Therapeutics Inc. (DNLI)?

What is the highest PE Ratio for Denali Therapeutics Inc. (DNLI)?

What is the 3-year average PE Ratio for Denali Therapeutics Inc. (DNLI)?

What is the 5-year average PE Ratio for Denali Therapeutics Inc. (DNLI)?

How does the current PE Ratio for Denali Therapeutics Inc. (DNLI) compare to its historical average?